Prospective studies using reported methods to detect the levels of BC200 in blood [75], would confirm its potential as a biomarker in the prognosis of breast cancer development/progression in high risk populations, such as women with a family history of breast cancer and BRCA-1 and/or BRCA-2 mutation carriers. Here, BRCA1 is linked to breast cancer.